Our main activity is testing novel nanosystems in in vivo PDX models by assessing their effectiveness on tumor growth, tumor dissemination, metastasis formation and on the potential therapeutic impact on the CSC subset.
We will also investigate the expression of candidate target TAS1R3 in primary tumors and PDX models, especially focusing on the co-expression of TAS1R3 (metastatic target) with CD133 (CSC marker).